{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:25:02Z","timestamp":1793193902586,"version":"4.5.0"},"reference-count":66,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Management of bleeding in hereditary hemorrhagic telangiectasia (HHT), the second most common hereditary bleeding disorder in the world, is currently undergoing a paradigm shift. Disease-modifying antiangiogenic therapies capable of achieving durable hemostasis via inducing telangiectasia regression have emerged as a highly effective and safe modality to treat epistaxis and gastrointestinal bleeding in HHT. While evidence to date is incomplete and additional studies are ongoing, patients presently in need are being treated with antiangiogenic agents off-label. Intravenous bevacizumab, oral pazopanib, and oral thalidomide are the three targeted primary angiogenesis inhibitors, with multiple studies describing both reassuring safety and impressive effectiveness in the treatment of moderate-to-severe HHT-associated bleeding. However, at present there is a paucity of guidance in the literature, including the published HHT guidelines, addressing the practical aspects of antiangiogenic therapy for HHT in clinical practice. This review article and practical evidence-based guide aims to fill this unaddressed need, synthesizing published data on the use of antiangiogenic agents in HHT, relevant data for their use outside of HHT, and expert guidance where evidence is lacking. After a brief review of principles of bleeding therapy in HHT, guidance on hematologic support with iron and blood products, and alternatives to antiangiogenic therapy, this article examines each of the aforementioned antiangiogenic agents in detail, including patient selection, initiation, monitoring, toxicity management, and discontinuation. With proper, educated use of antiangiogenic therapies in HHT, patients with even the most severe bleeding manifestations can achieve durable hemostasis with minimal side-effects, dramatically improving health-related quality of life and potentially altering the disease course.<\/jats:p>","DOI":"10.1055\/s-0042-1743467","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T19:33:16Z","timestamp":1646076796000},"page":"514-528","source":"Crossref","is-referenced-by-count":29,"title":["Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians"],"prefix":"10.1055","volume":"48","author":[{"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"A Kritharis","year":"2018","journal-title":"Haematologica"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","author":"R S Kasthuri","year":"2017","journal-title":"Am J Hematol"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"M E Faughnan","year":"2011","journal-title":"J Med Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"D W Leung","year":"1989","journal-title":"Science"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"N Ferrara","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"A Cirulli","year":"2003","journal-title":"Acta Haematol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"H Al-Samkari","year":"2020","journal-title":"Blood"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"173","author":"M E Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"J B Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"L X Yin","year":"2016","journal-title":"Laryngoscope"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/rth2.12444","article-title":"A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders","volume":"4","author":"H Al-Samkari","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0021-9258(18)72406-X","article-title":"The iron content of crystalline human hemoglobin","volume":"147","author":"F W Bernhart","year":"1943","journal-title":"J Biol Chem"},{"issue":"02","key":"ref13","first-page":"35","article-title":"Determination of iron content in different hemoglobin samples from some patients by UV-visible spectrophotometer","volume":"6","author":"I EH Elgailani","year":"2016","journal-title":"Adv Anal Chem"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1538-7836.2007.02531.x","article-title":"Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers","volume":"5","author":"C Sabb\u00e0","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.meg.0000252633.88419.04","article-title":"Assessment of intestinal vascular malformations in patients with hereditary hemorrhagic teleangiectasia and anemia","volume":"19","author":"S A van Tuyl","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.gie.2009.11.004","article-title":"High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and\/or severe anemia","volume":"71","author":"E Gr\u00e8ve","year":"2010","journal-title":"Gastrointest Endosc"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/gim.2013.62","article-title":"Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes","volume":"16","author":"C Canzonieri","year":"2014","journal-title":"Genet Med"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1572-0241.2000.01792.x","article-title":"Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"95","author":"A D Kjeldsen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref19","first-page":"4798425","article-title":"Impact of age on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia","volume":"2018","author":"V N Iyer","year":"2018","journal-title":"Adv Hematol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajmg.1320320302","article-title":"Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population","volume":"32","author":"H Plauchu","year":"1989","journal-title":"Am J Med Genet"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/alr.21287","article-title":"Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu)","volume":"4","author":"J E Hanks","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2500\/ajra.2015.29.4163","article-title":"Radiofrequency ablation for treatment of hereditary hemorrhagic telangiectasia lesions: \u201cHow I do it\u201d","volume":"29","author":"B Rotenberg","year":"2015","journal-title":"Am J Rhinol Allergy"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"E1507","DOI":"10.3390\/jcm9051507","article-title":"Trauma can induce telangiectases in hereditary hemorrhagic telangiectasia","volume":"9","author":"U Geisthoff","year":"2020","journal-title":"J Clin Med"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.otohns.2008.01.005","article-title":"Long-term complications of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia","volume":"138","author":"C G Levine","year":"2008","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4193\/Rhin16.315","article-title":"Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience","volume":"55","author":"V J Lund","year":"2017","journal-title":"Rhinology"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"K J Whitehead","year":"2016","journal-title":"JAMA"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4193\/Rhin17.166","article-title":"Intranasal bevacizumab in the treatment of HHT-related epistaxis: a systematic review","volume":"56","author":"P Stokes","year":"2018","journal-title":"Rhinology"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.0954-6820.1981.tb11614.x","article-title":"Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial","volume":"209","author":"P Vase","year":"1981","journal-title":"Acta Med Scand"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"bcr1120103534","DOI":"10.1136\/bcr.11.2010.3534","article-title":"Rendu-Osler disease: treatment with oestrogen\/progestagen versus octreotide","volume":"2011","author":"S Jeanneret","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2004.07.050","article-title":"Pica and food craving in patients with iron-deficiency anemia: a case-control study in France","volume":"118","author":"A Kettaneh","year":"2005","journal-title":"Am J Med"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1503\/cmaj.110950","article-title":"Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial","volume":"184","author":"P Vaucher","year":"2012","journal-title":"CMAJ"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2005.11.1104","article-title":"The diagnosis and treatment of iron deficiency and its potential relationship to hair loss","volume":"54","author":"L B Trost","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"J A Livesey","year":"2012","journal-title":"Thorax"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2020.01313","article-title":"Iron deficiency anemia at time of vaccination predicts decreased vaccine response and iron supplementation at time of vaccination increases humoral vaccine response: a birth cohort study and a randomized trial follow-up study in Kenyan infants","volume":"11","author":"N U Stoffel","year":"2020","journal-title":"Front Immunol"},{"issue":"07","key":"ref36","first-page":"301","article-title":"Intravenous iron-dextran: therapeutic and experimental possibilities. [in German]","volume":"100","author":"A M Ganzoni","year":"1970","journal-title":"Schweiz Med Wochenschr"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH06-07-0373","article-title":"Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1\/endoglin pathway in endothelial cells","volume":"97","author":"A Fernandez-L","year":"2007","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"S Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"U W Geisthoff","year":"2014","journal-title":"Thromb Res"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00277-014-2169-y","article-title":"The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey","volume":"94","author":"N Zaffar","year":"2015","journal-title":"Ann Hematol"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-020-01453-1","article-title":"Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding","volume":"15","author":"J D Beckman","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey","volume":"153","author":"S Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","author":"J G Parambil","year":"2021","journal-title":"Angiogenesis"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"H Al-Samkari","year":"2021","journal-title":"Blood"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"H Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"V N Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"H Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"09","key":"ref48","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"S Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"H Al-Samkari","year":"2020","journal-title":"Haemophilia"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.mayocp.2020.03.001","article-title":"Intravenous bevacizumab in hereditary hemorrhagic telangiectasia-related bleeding and high-output cardiac failure: significant inter-individual variability in the need for maintenance therapy","volume":"95","author":"H AH Albitar","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients","volume":"12","author":"A Guilhem","year":"2017","journal-title":"PLoS One"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"M E Faughnan","year":"2019","journal-title":"Angiogenesis"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"F Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"22","key":"ref54","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.4103\/0366-6999.169068","article-title":"Thalidomide effects in patients with hereditary hemorrhagic telangiectasia during therapeutic treatment and in Fli-EGFP Transgenic Zebrafish Model","volume":"128","author":"H L Peng","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: a preliminary study","volume":"157","author":"J Fang","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"R Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow-up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia","volume":"53","author":"A Hosman","year":"2015","journal-title":"Rhinology"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2018.2018.0190","article-title":"Thalidomide for the management of bleeding episodes in patients with hereditary hemorrhagic telangiectasia: effects on epistaxis severity score and quality of life","volume":"36","author":"M Baysal","year":"2019","journal-title":"Turk J Haematol"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"E Buscarini","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/0194599818813521","article-title":"Systemic bevacizumab for hereditary hemorrhagic telangiectasia: considerations from observational studies","volume":"160","author":"H Al-Samkari","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"H Al-Samkari","year":"2019","journal-title":"J Intern Med"},{"key":"ref62","year":"2017"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"H Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"issue":"07","key":"ref64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI6740","article-title":"VEGF(165) mediates glomerular endothelial repair","volume":"104","author":"T Ostendorf","year":"1999","journal-title":"J Clin Invest"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/gut.2003.029710","article-title":"Thalidomide for treatment of severe intestinal bleeding","volume":"53","author":"J Bauditz","year":"2004","journal-title":"Gut"},{"issue":"22","key":"ref67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V128.22.210.210","article-title":"Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a Phase I study","volume":"128","author":"M Samour","year":"2016","journal-title":"Blood"},{"key":"ref68","volume-title":"US FDA","year":"2021"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1743467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T01:39:25Z","timestamp":1700271565000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1743467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":66,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1743467","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}